SILONCMHealthcare·Biotechnology#537 in industry

Silo Pharma, Inc.

+18.4% · 90d

$0.44

-0.06 (-12.40%)

After-Hours $0.45(+0.01)

News

(1)

April 2026

Apr 10, 20262 weeks agoPOS AMHealthcare

SILO Files Amendment for Warrant Resale Amid Digital Asset Shift

SILOSilo Pharma, Inc.

# 🧾 What This Document Is This is a **Post-Effective Amendment** to a registration statement. Think of it as a mandatory update to a previously approved document. Silo Pharma is refreshing its paperwork with the SEC to include its 2025 financial statements and to keep the registration alive. This s

Read summaryView on SEC EDGAR

Key Data

Market Cap$7.1M

Open$0.48

Prev Close$0.50

Day Range$0.42 – $0.48

52W Range$0.22 – $1.15

Volume880,053

P/E (TTM)—

EPS$-0.50

Dividend Yield—

Beta0.59

About

Silo Pharma Inc. operates as a developmental stage biopharmaceutical company. The company is developing therapeutics that address underserved conditions, including post-traumatic stress disorder (PTSD), stress-induced anxiety disorders, fibromyalgia, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in formulations. The company's lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders. It is also developing SP-26, a time-release ketamine-loaded implant for fibromyalgia and chronic pain relief. In addition, the company's two preclinical programs comprise SPC-14, an intranasal compound for the treatment of Alzheimer's disease, and SPU-16, a CNS-homing peptide targeting multiple sclerosis (MS). The company's research and development programs are conducted through collaborations with Columbia University, Medspray Pharma BV, and the University of Maryland, Baltimore. The company was formerly known as Uppercut Brands, Inc. and changed its name to Silo Pharma, Inc. in September 2020. Silo Pharma, Inc. was incorporated in 2010 and is based in Sarasota, Florida.

Healthcare · Biotechnology

3 employees

silopharma.com